Charles Schwab Investment Management Inc. Trims Holdings in Senseonics Holdings, Inc. (NYSE:SENS)

Charles Schwab Investment Management Inc. decreased its position in shares of Senseonics Holdings, Inc. (NYSE:SENS) by 1.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,064,856 shares of the company’s stock after selling 45,234 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Senseonics were worth $1,072,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of SENS. GSA Capital Partners LLP bought a new stake in Senseonics during the 3rd quarter valued at approximately $117,000. Cubist Systematic Strategies LLC boosted its stake in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the period. Finally, Symmetry Partners LLC purchased a new stake in Senseonics during the 3rd quarter valued at approximately $164,000. 12.36% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Frederick T. Sullivan acquired 124,933 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Timothy T. Goodnow bought 315,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were bought at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the transaction, the chief executive officer now owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. The trade was a 2.86 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Senseonics Price Performance

Shares of Senseonics stock opened at $0.42 on Wednesday. The firm has a market cap of $249.74 million, a PE ratio of -3.23 and a beta of 0.77. The stock has a 50 day moving average of $0.33 and a 200 day moving average of $0.37. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics Holdings, Inc. has a 12 month low of $0.25 and a 12 month high of $0.75.

Analysts Set New Price Targets

Several research firms have recently commented on SENS. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Friday, November 15th. StockNews.com began coverage on shares of Senseonics in a research note on Wednesday. They issued a “sell” rating on the stock.

Senseonics Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.